Latest Capital Raises News

ActivEX Limited has completed a $100,000 share placement with Business Victor Investments Limited, aiming to accelerate its exploration activities and strengthen working capital.

Corella Resources has completed the first tranche of a $1 million share placement, issuing over 142 million shares at $0.0035 each. The second tranche and attached options await shareholder approval in early 2026.

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

Pure Resources has completed a $1.7 million placement to fund its Garnet Hills Garnet and Graphite Project, with options to be issued pending shareholder approval.

DevEx Resources has successfully raised nearly $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $3 million target to fund expanded uranium exploration in Australia’s Northern Territory.

Globe Metals & Mining has issued over 56 million shares to Director Bo Tan, settling nearly all of an outstanding loan and achieving a fully debt-free status. This financial milestone positions the company strongly for advancing its Kanyika Niobium Project.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Kinetiko Energy has secured approval to trade on the North American OTCQB Market, aiming to boost investor access and liquidity as it advances its South African gas projects.

American Tungsten & Antimony Ltd plans to unlock value by spinning out its Drummond Basin and NSW gold exploration assets into a new ASX-listed company, King Metals Limited, aiming to raise up to $6 million in an IPO.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.